Company profile: Enable Injections
1.1 - Company Overview
Company description
- Provider of on-body wearable drug delivery systems enabling patients to self-administer large amounts of medication. Products include the enFuse wearable delivery system with constant-pressure delivery and a progress gauge; Smart enFuse with Bluetooth connectivity for data transmission to a smartphone app; and syringe/vial transfer systems for mixing and transferring medication, including dual-vial and automatic reconstitution options.
Products and services
- Automatic Reconstitution Transfer System: Fully automated system that mixes medication from vials and transfers it into the enFuse for on-body self-administration, automating reconstitution and the vial-to-device transfer workflow
- EnFuse® Wearable Delivery System: Constant-pressure wearable on-body system enabling patients to self-administer large amounts of medication, featuring a delivery progress gauge for precise dosing feedback and controlled flow
- Smart enFuse®: Bluetooth-enabled wearable device for on-body medication administration, transmitting delivery data to a smartphone app for digital tracking and patient feedback during self-administration
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Enable Injections
Alliqua
HQ: United States
Website
- Description: Provider of biomedical products and therapies, including custom electron-beam cross-linked hydrogels for medical and cosmetic applications and the UltraMIST ultrasound wound-healing therapy; develops, manufactures, and markets proprietary products leveraging a technology portfolio.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alliqua company profile →
MannKind
HQ: United States
Website
- Description: Provider of inhaled and wearable therapeutic products and platforms for diabetes and pulmonary diseases, including Afrezza (inhaled insulin), Tyvaso DPI (treprostinil for PAH and PH-ILD), Clofazimine Inhalation Suspension (for NTM lung disease), Nintedanib DPI (for pulmonary fibrotic diseases), V-Go (wearable insulin delivery), and Technosphere Technology for dry powder inhalation formulations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MannKind company profile →
Corsair Pharma
HQ: United States
Website
- Description: Provider of a transdermal treprostinil prodrug patch for pulmonary arterial hypertension (PAH), designed to deliver consistent blood levels and reduce the need for invasive administration. Develops transformative solutions to improve the therapeutic profile of medications and provide superior treatment for patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corsair Pharma company profile →
Xeris Biopharma
HQ: United States
Website
- Description: Provider of pharmaceutical therapies in endocrinology, neurology, and gastroenterology, including Gvoke and Ogluo ready-to-use glucagon injections for severe hypoglycemia; Keveyis, the first FDA-approved treatment for Primary Periodic Paralysis; Recorlev for endogenous Cushing's syndrome; and levothyroxine for hypothyroidism. Ogluo is marketed in the UK/EU under an exclusive agreement with Tetris Pharma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xeris Biopharma company profile →
Qnovia
HQ: United States
Website
- Description: Provider of medtech and pharmaceutical drug-delivery solutions, including RespiRx, an inhalable prescription nicotine replacement therapy for smoking cessation; an inhaled drug delivery platform that optimizes and tracks dosing to improve efficacy and compliance; and a portable, orientation-agnostic vibrating mesh nebulizer with a digital metered dose interface, Bluetooth-enabled app, and a zero-maintenance disposable cartridge.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Qnovia company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Enable Injections
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Enable Injections
2.2 - Growth funds investing in similar companies to Enable Injections
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Enable Injections
4.2 - Public trading comparable groups for Enable Injections
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →